Implant protocol

Q: 51% with BOP<10%

N = 200 · RANDOMIZED, PEER-REVIEWED · 2026 In Stage I–III periodontitis patients on supportive periodontal care (SPC), reduction in key measurements were greater with home-applied dual-light therapy as an adjunct to SPC than in SPC alone. At 6 months, 51% of participants with the SPC+dual-light had BOP<10%, versus 23% with SPC alone. At 6 months, 63% had visible plaque (VPI) <10% with the SPC+dual-light, versus 38% with SPC alone. The number of sites with PPD ≥4 mm was also lower with SPC+dual-light. Pakarinen S et al. Journal of Periodontology. 2026. DOI: 10.1002/jper.70082

Q: Str. mutans reduction

IN VITRO · PEER-REVIEWED · 2020 In a Streptococcus mutans biofilm model, a single dual-light exposure produced a four-log reduction in bacterial counts. More importantly for daily home use, repeated single-modality treatment allowed biofilm adaptation over time, whereas the dual-light combination prevented that adaptation and maintained its bactericidal effect across repeated exposures. In implant patients, where biofilm continuously reforms on implant surfaces and within the peri-implant sulcus, creating persistent and difficult-to-access microbial niches, the relevance of sustained efficacy across repeated exposures exceeds that of single-exposure performance. Nikinmaa S et al. PLoS ONE. 2020. DOI: 10.1371/journal.pone.0232775

Q: Significant BOP reduction in 2 weeks

N = 30 · RANDOMIZED, NON-PUBLISHED INTERIM RESULTS · 2026 In a randomized study on peri-implantitis patients, adjunctive use of Lumoral resulted in a consistent and statistically significant reduction in bleeding on probing at 2, 4, and 8 weeks of daily treatment. The treatment effect was equally evident in all six sites. Lumoral use resulted in a rapid, sustained, and statistically significant reduction in key inflammatory cytokines (TNF-α, IL-6, and IL-1β). The control group showed non-significant changes, indicating effective suppression of inflammatory activity. ClinicalTrials.gov: NCT06859866

Preoperative bacterial load

Implant success starts before surgery

Lumoral® assists with pre-operative stabilization prior to implant surgery by controlling biofilm and inflammatory burden in the period from treatment agreement until surgery can begin.

The HOPE CP study shows that Lumoral®, in addition to diligent dental care, can significantly shorten treatment time.

Early peri-implant inflammation

Implants rarely fail on day 1

Plaque around healing abutments and prosthetic contours can accelerate the inflammatory response during the healing phase.

Lumoral® helps patients reduce bacterial load and stimulates healing and blood supply in the surgical field.

Long-term risk

Failure between recalls

Peri-implant mucositis often arises as a home care problem long before it becomes a surgical problem.

Long-term success depends on a maintenance protocol the patient can actually follow.

Lumoral® studies show a high frequency of use throughout the study periods.

The patient spends most of their time outside the clinic

Professional treatment is crucial – but the biological change occurs between visits. Implant patients can spend months in an inflammatory risk zone before the next recall.

Control biofilm between visits

Lumoral® combines antibacterial blue light with photodynamic therapy to reduce plaque and inflammatory burden around implants.

ABL · 405 nm

Targets plaque-associated bacteria using antibacterial blue light.

APDT · 810 nm + ICG

ICG selectively binds to plaque and is activated by near-infrared light.

Suitable for maintenance

No antibiotic-based mechanism. Designed for repeated home use.

BOP 4.7 → 1.8 ↓

N = 40 · PEER-REVIEWED · 2025

In patients with newly diagnosed peri-implant disease, home dual-light therapy, adjunctive to traditional home-care, reduced bleeding on probing from 4.7% to 1.8% over 4 weeks (p < 0.0001). The control group showed no significant change. aMMP-8 also decreased in the treatment group, while it remained unchanged in controls. Gum inflammation is a threat to aligner patients, and it can cause long-lasting problems.

Lähteenmäki H et al. Clinical and Experimental Dental Research. 2025. DOI: 10.1002/cre2.70146

51% with BOP<10%

N = 200 · RANDOMIZED, PEER-REVIEWED · 2026

In Stage I–III periodontitis patients on supportive periodontal care (SPC), reduction in key measurements were greater with home-applied dual-light therapy as an adjunct to SPC than in SPC alone. At 6 months, 51% of participants with the SPC+dual-light had BOP<10%, versus 23% with SPC alone. At 6 months, 63% had visible plaque (VPI) <10% with the SPC+dual-light, versus 38% with SPC alone. The number of sites with PPD ≥4 mm was also lower with SPC+dual-light.

Pakarinen S et al. Journal of Periodontology. 2026. DOI: 10.1002/jper.70082

Str. mutans reduction

IN VITRO · PEER-REVIEWED · 2020

In a Streptococcus mutans biofilm model, a single dual-light exposure produced a four-log reduction in bacterial counts. More importantly for daily home use, repeated single-modality treatment allowed biofilm adaptation over time, whereas the dual-light combination prevented that adaptation and maintained its bactericidal effect across repeated exposures. In implant patients, where biofilm continuously reforms on implant surfaces and within the peri-implant sulcus, creating persistent and difficult-to-access microbial niches, the relevance of sustained efficacy across repeated exposures exceeds that of single-exposure performance.

Nikinmaa S et al. PLoS ONE. 2020. DOI: 10.1371/journal.pone.0232775

Significant BOP reduction in 2 weeks

N = 30 · RANDOMIZED, NON-PUBLISHED INTERIM RESULTS · 2026

In a randomized study on peri-implantitis patients, adjunctive use of Lumoral resulted in a consistent and statistically significant reduction in bleeding on probing at 2, 4, and 8 weeks of daily treatment. The treatment effect was equally evident in all six sites. Lumoral use resulted in a rapid, sustained, and statistically significant reduction in key inflammatory cytokines (TNF-α, IL-6, and IL-1β). The control group showed non-significant changes, indicating effective suppression of inflammatory activity.

ClinicalTrials.gov: NCT06859866